Confronto
Cagrilintide vs. Retatrutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
1415456-99-3
2381089-83-2
Peso molecolare
4253.7 g/mol
4731.6 g/mol
Emivita
168 h
144 h
Sequenza
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYY-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSMeccanismo d'azione
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
5
di cui sull'uomo
3
4
Effetti registrati
3
4
Contraddizioni aperte
1
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Cagrilintide and Retatrutide?
- Cagrilintide is classified as "Metabolico", while Retatrutide is classified as "Metabolico". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Retatrutide?
- The highest available evidence level is "RCT sull'uomo" for Cagrilintide and "RCT sull'uomo" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Retatrutide in Germany and the United States?
- Germania: Cagrilintide — Non approvato, Retatrutide — Non approvato. Stati Uniti: Cagrilintide — Non approvato, Retatrutide — Non approvato. These are factual summaries with source and review date on the individual pages.